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Background
Patients with HIV RNA suppression below 50 copies/
mL may still have HIV RNA detectable by more sensi-
tive PCR assay techniques.
Methods
In the MONET trial, 256 patients with HIV RNA <50
copies/mL on current HAART, and no history of viro-
logical failure, switched to DRV/r 800/100 mg once
daily, either as monotherapy (n=127) or with 2NRTI
(n=129). HIV RNA was evaluated by the Roche Ampli-
cor Ultrasensitive assay (lower detection limit=50
copies/mL), for all patient visits to Week 96. With this
assay, “Optical Density=background” was used to
assess whether HIV RNA was detectable or undetect-
able below 50 copies/mL.
Results
Patients were 81% male, 91% Caucasian, and had med-
ian baseline CD4 count of 575 cells/uL. At the baseline
visit, the percentage of patients with HIV RNA unde-
tectable below 50 copies/mL (OD=background) was 80%
in the DRV/r mono arm and 79% in the DRV/r +
2NRTI arm. The percentage with HIV RNA at different
levels at the Week 96 visit is shown in Table 1
(observed data analysis)
Including all samples from patient visits from Week 4
to Week 96, HIV RNA was above 50 copies/mL in 69/
1009 samples in the DRV/r monotherapy arm (50-400:
84%, 400-1000: 12%, >1000: 4%) and 47/1051 samples in
the DRV/r + 2NRTI arm (50-400: 83%, 400-1000: 8.5%,
>1000: 8.5%).
Conclusions
In this study for patients with HIV RNA <50 copies/mL
at baseline, switching to DRV/r monotherapy showed
similar levels of HIV RNA suppression to DRV/r +
2NRTIs, using more sensitive PCR assay techniques.
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Table 1
HIV RNA DRV/r mono
(n=105)
DRV/r + 2NRTIs
(n=114)
HIV RNA <50, OD =
background
79.0% 80.7%
HIV RNA <50, detectable 17.1% 14.9%
HIV RNA 50-400 copies/mL 2.9% 3.5%
HIV RNA <400 copies/mL 1.0% 0.9%
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